
Keywords: CBL; casitas B-lineage lymphoma; CtxR; cetuximab-resistant; CtxS; cetuximab-sensitive; CRC; colorectal cancer; EGF; epidermal growth factor; EGFR; epidermal growth factor receptor; EMT; epithelial to mesenchymal transition; EPR; epiregulin; FDA; food and